Abstract 3504
Background
New hormonal agents (NHA) have been widely used to treat patients with metastatic and non-metastatic CRPC, with abiraterone, enzalutamide and apalutamide being FDA approved. Falls and fractures are common adverse events (AEs) observed in these patients. We conducted a meta-analysis of randomized controlled trials (RCTs) to characterize the incidence and relative risks (RRs) of falls/fractures associated with these drugs.
Methods
PubMed, Cochrane, Embase, abstracts presented at annual meeting of the ASCO and ESMO were searched for articles published from 2005 to December 2018. Eligible studies included phase II and III RCT of abiraterone, enzalutamide and apalutamide. Safety profile from selected studies was evaluated for all-grade and high-grade falls/fractures. Summary incidences and RR, with 95% confidence intervals, of all-grade and high-grade events were calculated using random-effects or fixed-effects model based on the heterogeneity of selected studies.
Results
5 RCT with adequate safety profile reporting on falls/fractures were selected and included a total of 6,695 patients. 2,500 patients received placebo/control and 4,195 patients received NHA. The incidence of all-grade falls for control arm and NHA arm was 5.0% and 10.0%, respectively. There was a significant increase in the risk of all-grade and high-grade falls with RR of 2.02 (95% CI 1.66-2.45; p < 0.0001) and 2.10 (95% CI 1.11-3.99; p = 0.0226), respectively. The incidence of all-grade fractures was 3.0% in control arm and 8.0% in NHA arm. There was a significant increase in the risk of all-grade and high-grade fractures with RR of 2.30 (95% CI 1.77-2.99; p < 0,0001) and 2.11 (95%CI 1.18-3.74; p = 0.0111), respectively.
Conclusions
NHAs are associated with higher risk of falls and fractures compared to placebo. However, it should be assessed with caution as the total observation time in the NHA arms were usually longer than with placebo. We could not investigate the mechanisms involved in falls, but we speculate that an effect in balance or fatigue/sarcopenia secondary to profound androgen deprivation may play a role. Moreover, fractures in CRPC patient population may impact quality of life and mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract